OPRX OptimizeRx
- 5.490
- +0.280+5.37%
- 5.490
- 0.0000.00%
OptimizeRx News
Lake Street Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $11
Stifel Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $8
Stifel Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $8
B.Riley Financial Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $13
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $8
Optimistic Buy Rating for OptimizeRx Amid Leadership Transition and Strong Financial Outlook
Stephens Maintains OptimizeRx(OPRX.US) With Hold Rating, Cuts Target Price to $5.5
OptimizeRx Analyst Ratings
OptimizeRx Initiated With an Equal Weight at Stephens
Lake Street Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $11
Analysts Conflicted on These Healthcare Names: OptimizeRx (OPRX) and Universal Health (UHS)
Stifel Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $8
Roth MKM Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $16
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Ontrak (OTRK) and Ayr Wellness (OtherAYRWF)
OptimizeRx Is Maintained at Market Outperform by JMP Securities
OptimizeRx Analyst Ratings
RBC Capital Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $7
Barclays Sticks to Their Hold Rating for OptimizeRx (OPRX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: PTC Therapeutics (PTCT), Medtronic (MDT) and OptimizeRx (OPRX)
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Cuts Target Price to $8
No Data